Skip to main content
  • About Us
  • Science & Portfolio
  • Patients & Families
  • Team
  • News & Events
  • Careers
  • Contact
Copyright © 2023 Kisbee Therapeutics, LLC. All Rights Reserved.
Redefining Treatment

Harnessing Lipid Biology to Protect and Repair CNS Function

About Us

At Kisbee Therapeutics, we are engineering recombinant lipoproteins to target the core biological systems underlying neurodegenerative diseases. Our work represents a novel approach to address the problem of lipid dysregulation observed across many CNS (central nervous system) diseases.

Science & Portfolio

Genetically Validated Approach to Restore Lipid Homeostasis

A growing body of scientific evidence has linked dysfunctional lipid biology to the onset and severity of neurodegenerative disease.

Human genetics has shown that ineffective lipoprotein function as well as mutations in lipid transport genes are central drivers of neurodegeneration. Failure to properly regulate lipid transport between neurons, astrocytes, and microglia leads to excitotoxicity, impaired debris clearance, protein accumulation, inflammation, and reduced lysosomal function, all hallmarks of many neurodegenerative diseases.

By use of our highly optimized, engineered lipoproteins, also known as Kisbee Discs, we are able to intervene and restore lipid homeostasis – gathering and transporting lipids to where they are needed.

Kisbee is focused on advancing programs where we can use biomarkers to connect relevant biology in genetically defined patient populations to improve our ability to demonstrate efficacy and to further characterize the potential therapeutic benefit of our approach. Alzheimer’s disease, along with several other rare, chronic, and acute neurodegenerative conditions, are in focus for initial therapeutic development efforts.

Patients & Families

At Kisbee, we have a shared mission with the patient communities we serve to develop new and impactful therapies. We know this mission is best achieved by working together and by having the patient’s perspective of the diseases we are researching.

Our Commitment

To listen, really listen, to the patient communities we serve to understand unmet needs and your lived experience

To be transparent about our work

To actively partner with advocacy organizations globally throughout the drug development process

If you have questions or would like to connect with a member of our patient advocacy team, please contact us at patients@kisbeetx.com

Founders

Meet the experts behind our vision

Stuart Schreiber headshot
Stuart Schreiber, PhD
Co-Founder
Banjamin Cravatt headshot
Benjamin Cravatt, PhD
Co-Founder
Jennifer Lippincott-Schwartz headshot
Jennifer Lippincott-Schwartz, PhD
Co-Founder
Emily Ricq headshot
Emily Ricq, PhD
Co-Founder & Vice President, Discovery Biology

Leadership Team

Matt Ottmer headshot
Matt Ottmer
Chief Executive Officer & Director
Ted Keysor headshot
Ted Keysor
Chief Operating Officer
Mathew Pletcher headshot
Mathew Pletcher, PhD
Chief Scientific Officer
Doug Feltner headshot
Douglas Feltner, MD
Chief Medical Officer
Emily Ricq headshot
Emily Ricq, PhD
Co-Founder & Vice President, Discovery Biology
Bill Avery headshot
Bill Avery, PhD
SVP, Translational Development
Elsie DiBella headshot
Elsie DiBella, PhD
SVP, Technical Operations
Albert Lo headshot
Albert Lo, MD, PhD
SVP, Translational Medicine & Clinical Development

Board of Directors

Matt Ottmer headshot
Matt Ottmer
Chief Executive Officer & Director
Kristina Burow headshot
Kristina Burow
Managing Director, Arch Venture Partners
Thomas Cahill headshot
Thomas Cahill, MD, PhD
Managing Director, Newpath Partners
Gudarz Davar headshot
Gudarz Davar, MD
Chief Medical Officer, Autobahn Therapeutics

Investors

Arch Venture Partners
Newpath Partners

Publications

  • Cell Stem Cell (2022): Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity
  • Molecular Psychology (2022): Brain integrity is altered by hepatic APOE ε4 in humanized-liver mice
  • Nature Neuroscience (2022): Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function
  • Cell (2022): Cholesterol and matrisome pathways dysregulated in astrocytes and microglia
  • PNAS (2021): Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol

Careers

Join us in creating a new class of therapeutics for neurodegenerative disease

Kisbee is developing lipid-based therapeutics for neurodegenerative diseases and CNS injuries by bringing together passionate scientists and drug developers. Our diverse experiences and perspectives enable us to support and challenge one another, fostering care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. We are passionate and driven, and we aspire to overcome obstacles with creativity and careful risk-taking, striving to make a difference for patients.

We Value

Inherent Trust

We show up, we speak with honesty and deliver what we promise. We are confident in one another’s capabilities, display integrity in all things, and assume best intent knowing that we each keep everyone’s best interests at heart

Unconditional Respect

We embrace our different backgrounds, experiences, and viewpoints to strengthen our fabric and enhance our outcomes. Our interactions are driven by universal compassion, so we act with humility and a willingness to understand everyone’s perspective

Unabashed Curiosity

We leverage our relentless passion for our patients, our business, and our science by creatively looking at things through a different lens, humbly considering alternatives, and remaining eager to learn

Thoughtful Transparency

We share what we should, when we should. We trust each other to demonstrate sound discernment and to honor the best interests of the individuals when sharing

Fearless Pursuit

We exercise mature judgment so we’re entrusted to think, experiment, and discover for ourselves. We’re not afraid to take informed risks, embrace challenges, and push boundaries in order to grow Kisbee and support patients

We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com

Join Our Team

Contact

Email: info@kisbeetx.com
Elsie DiBella headshot

Elsie DiBella, PhD

SVP, Technical Operations

Elsie DiBella joined Kisbee in May 2022 as the Senior Vice President of Technical Operations, bringing more than 25 years of industry experience in biologics development and manufacturing. Elsie has worked on more than 20 biologics from the preclinical stage through post-approval changes.

Most recently, she was the Vice President of Manufacturing and Development at ContraFect Corporation. Prior to joining ContraFect, Elsie was the Head of Biologics Process and Analytical Development at Momenta Pharmaceutical overseeing a portfolio of both novel and biosimilar biologics. Previously, she held roles of increasing responsibility within Process Development and Manufacturing Sciences at Shire Pharmaceuticals, Centocor Pharmaceuticals and Bristol-Myers Squibb. While at Shire Pharmaceuticals, Elsie contributed to global marketing authorization submissions and post-approval supplements for VPRIV®, Replagal® and Elaprase®. While at Centocor Pharmaceuticals, she was responsible for the late-stage purification process development of and contributed to the BLAs for Simponi® and Stelara®.

Elsie received her B.S. in Chemistry from Bates College and her PhD in Biophysical Chemistry from Cornell University in the laboratory of late Harold Scheraga.

Copyright © 2023 Kisbee Therapeutics, Inc. All Rights Reserved.
Privacy Policy
  • About Us
  • Science & Portfolio
  • Patients & Families
  • Team
  • News & Events
  • Careers
  • Contact